JBJulie Blatt

Julie Blatt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julie Blatt has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States

    by Bryan A. Sisk, Whitney Eng, Jamie Aye, Joana Mack, Andrew Tran, Jayme Ogino, Erika Pearson, Joshua Bies, Gayle Smink, Sonal D. Shah, et al.

    Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.


  • Variants of Uncertain Significance in Vascular Anomalies: The Role of Reclassification

    by Julie Blatt, Clara Hildebrandt, Elizabeth Nieman, Michael C. Adams, Lucy McNamee, Alexandra J. Borst

    Background: Vascular anomalies (VA) are rare developmental disorders due to somatic variants in intracellular growth signaling pathways. Although genetic evaluation is considered the standard of care for optimizing management, the frequency of variants of uncertain significance (VUS) in VA and their clinical implications are not defined. Methods: Medical records were reviewed on all patients seen in our VA clinic from January 2014 to August 2024 with vascular malformations or related disorders who had undergone genetic testing. The year and patient age at the time of genetic testing, whether testing was done on peripheral blood or involved tissue, and results were noted. Laboratory vendors were queried about policies for reclassifying VUS and selective re‐evaluations of VUS were requested. Results: In all, 154 patients underwent single gene or gene panel evaluations, with the number of patients tested increasing from zero in 2014 to 39 in 2023; 21 patients had testing done during the first 7 months of 2024. VUS were reported in 22 patients (14%). Many laboratory vendors maintain a policy of revisiting these nonpathogenic variants only when requested by the treating physician. Unsolicited reclassification was reported in a single patient whose VUS was found to be a normal variant. No changes were identified in six other patients whose VUS were re‐examined. Conclusions: VUS are not uncommon in VA. Reclassification may be possible as more variant‐specific data become available and more testing is performed. Centers need to be aware that reclassification efforts are not automatic and should be considered where changes in therapy might result.

  • Hemolytic Crisis in SCD

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    Laboratory features of hemolytic crises in SCD and the need to think about delayed hemolytic transfusion reactions are noted. Whether or not to transfuse is discussed.

  • Sickle Cell Emergencies

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    Recognizing that there are whole books written on this topic, this section is a quick summary of how to determine if a patient is experiencing one or more types of crises. After a brief overview, specific subsections deal with the treatment of acute chest syndrome, aplastic crisis, hemolytic crisis, pain, priapism, sequestration, and stroke. The reader is directed to other relevant sections including Fever in High-Risk Populations, Transfusion Emergencies, Severe Anemia, and Hemolytic Anemias.

  • What To Do When a Patient Dies

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    This section is the corollary to the prior section, “Managing Symptoms at the End of Life,” and provides a step-by-step guide to pronouncing a child at the time of death. It also summarizes what else needs to be done, including permissions for autopsy, organ donation, and funeral arrangements—all the things we don’t like to think about but sometimes have to.

  • Acute Chest Syndrome

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    Acute chest syndrome is recognized as the most common cause of death in SCD. Features leading to early suspicion, confirmation of diagnosis with recommendations for management are offered.

  • Vitamin K Deficiency

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    This is rarely an overnight emergency but severe bleeding can occur, especially with a growing antagonism by families to vitamin K shots in the delivery room. The learner is reminded that this is done to avoid hemorrhagic disease of the newborn, a problem commonly seen before the 1960s when vitamin K administration in the delivery room was mandated in the US, but which is making a comeback. Other causes are reviewed and diagnostic work-up and recommendations for management are provided.

  • Managing Symptoms at the End of Life

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    This section and its companion, “What To Do When a Patient Dies,” address the nitty-gritty of how to approach this critical but often neglected and frequently uncomfortable scenario in children with life-threatening blood and cancer disorders. The stages and symptoms of dying are discussed with recommendations for symptom management. The need for anticipatory counseling for the family is emphasized.

  • Heparin Induced Thrombocytopenia (HIT)

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    As a cause of thrombosis/stroke requiring urgent attention, recognition of HIT is key in patients who are on anticoagulation with heparins but also even when heparin exposure is limited to KVO treatment of peripheral intravenous lines and rarely in patients who have never been exposed to heparins. Risk stratification using the 4T score and bulleted evaluation and treatment highlights are presented.

  • COVID-19 and Hematologic Emergencies

    by Julie Blatt, April M. Evans, Jessica Benjamin-Eze

    COVID-19 and the closely related multi-inflammatory syndrome in children (MIS-C) continue to be round-the-clock issues, especially in unvaccinated and other at-risk immunocompromised individuals such as those typically seen on PHO in-patient services. The role of PHO is often consultative since children most commonly will be admitted to a general pediatric floor or PICU, and most of the questions relate to COVID-19 as a hypercoagulable state with increased risk for thromboembolic phenomena. Risk factors are summarized, and NIH guidelines for prophylaxis and treatment are provided with links for further reading.